ABO subgroup incompatibility with severe hemolysis after consecutive allogeneic stem cell transplantations.

A1/A2 subtyping of blood group A ABO incompatibility allogeneic hematopoietic stem cell transplantation hemolysis

Journal

EJHaem
ISSN: 2688-6146
Titre abrégé: EJHaem
Pays: United States
ID NLM: 101761942

Informations de publication

Date de publication:
May 2021
Historique:
received: 06 01 2021
revised: 10 03 2021
accepted: 12 03 2021
entrez: 18 7 2022
pubmed: 24 3 2021
medline: 24 3 2021
Statut: epublish

Résumé

Allogeneic hematopoietic stem cell transplantations (HSCTs) represent a curative strategy for treating hematologic malignancies yet bear dangerous and frequently life-threatening complications including the development of graft-versus-host disease. Here, we present a case of a patient that suffered from relapsed/refractory multiple myeloma, a hematologic neoplasm characterized by clonal proliferation of malignant plasma cells in the bone marrow. During the course of his disease, the patient underwent consecutive allogeneic HSCTs, during which he developed a clinical meaningful and hitherto unreported ABO subgroup incompatibility, leading to persistent hemolysis. Testing for ABO subgroups during donor selection, especially after consecutive allogeneic HSCTs, may therefore aid to prevent these complications.

Identifiants

pubmed: 35845280
doi: 10.1002/jha2.190
pii: JHA2190
pmc: PMC9175969
doi:

Types de publication

Case Reports

Langues

eng

Pagination

280-284

Informations de copyright

© 2021 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.

Déclaration de conflit d'intérêts

The authors declare no competing financial interests.

Références

Blood Adv. 2018 Oct 9;2(19):2550-2553
pubmed: 30291113
Eur J Intern Med. 2011 Jun;22(3):220-9
pubmed: 21570637
Bone Marrow Transplant. 1997 Jun;19(11):1155-6
pubmed: 9193761
Curr Opin Hematol. 2007 Nov;14(6):664-70
pubmed: 17898572
Br J Haematol. 2008 Apr;141(2):149-69
pubmed: 18318765
Lancet. 2016 Apr 9;387(10027):1551-1560
pubmed: 26778538
Bone Marrow Transplant. 2008 Jul;42(1):67-9
pubmed: 18347568
BMC Genomics. 2016 May 20;17:374
pubmed: 27207383
JAMA. 2010 Apr 28;303(16):1617-24
pubmed: 20424252

Auteurs

Judith S Hecker (JS)

Department of Medicine III, Hematology and Internal Oncology, TUM School of Medicine Technical University of Munich Munich Germany.

Adam Wahida (A)

Department of Medicine III, Hematology and Internal Oncology, TUM School of Medicine Technical University of Munich Munich Germany.
Torsten-Haferlach-Leukemia-Diagnostics Foundation Munich Germany.

Erik Hameister (E)

Institute of Clinical Chemistry and Pathobiochemistry TUM School of Medicine Technical University of Munich Munich Germany.
Department of Medical Oncology and Hematology University of Zurich and University Hospital Zurich Zurich Switzerland.

Aneta Filo (A)

Institute of Clinical Chemistry and Pathobiochemistry TUM School of Medicine Technical University of Munich Munich Germany.

Jürgen Ruland (J)

Institute of Clinical Chemistry and Pathobiochemistry TUM School of Medicine Technical University of Munich Munich Germany.

Florian Bassermann (F)

Department of Medicine III, Hematology and Internal Oncology, TUM School of Medicine Technical University of Munich Munich Germany.

Martin Hildebrandt (M)

Institute of Clinical Chemistry and Pathobiochemistry TUM School of Medicine Technical University of Munich Munich Germany.
Department of Transfusion Medicine, Cellular Therapy and Hemostaseology University Hospital, LMU Munich Munich Germany.

Mareike Verbeek (M)

Department of Medicine III, Hematology and Internal Oncology, TUM School of Medicine Technical University of Munich Munich Germany.

Hendrik Poeck (H)

Department of Medicine III, Hematology and Internal Oncology, TUM School of Medicine Technical University of Munich Munich Germany.
Department of Internal Medicine III, Hematology and Internal Oncology University Hospital Regensburg Regensburg Germany.

Classifications MeSH